These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 26502932)

  • 1. A newly discovered Bordetella species carries a transcriptionally active CRISPR-Cas with a small Cas9 endonuclease.
    Ivanov YV; Shariat N; Register KB; Linz B; Rivera I; Hu K; Dudley EG; Harvill ET
    BMC Genomics; 2015 Oct; 16():863. PubMed ID: 26502932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary processing of CRISPR RNA by the endonuclease Cas6 in Staphylococcus epidermidis.
    Wakefield N; Rajan R; Sontheimer EJ
    FEBS Lett; 2015 Oct; 589(20 Pt B):3197-204. PubMed ID: 26364721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
    Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G
    BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
    He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
    Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the Origin of Reverse Transcriptase-Using CRISPR-Cas Systems and Their Hyperdiverse, Enigmatic Spacer Repertoires.
    Silas S; Makarova KS; Shmakov S; Páez-Espino D; Mohr G; Liu Y; Davison M; Roux S; Krishnamurthy SR; Fu BXH; Hansen LL; Wang D; Sullivan MB; Millard A; Clokie MR; Bhaya D; Lambowitz AM; Kyrpides NC; Koonin EV; Fire AZ
    mBio; 2017 Jul; 8(4):. PubMed ID: 28698278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate generation for endonucleases of CRISPR/cas systems.
    Zoephel J; Dwarakanath S; Richter H; Plagens A; Randau L
    J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
    Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
    mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragmentation of the CRISPR-Cas Type I-B signature protein Cas8b.
    Richter H; Rompf J; Wiegel J; Rau K; Randau L
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2993-3000. PubMed ID: 28238733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.
    Kennedy EM; Cullen BR
    Virology; 2015 May; 479-480():213-20. PubMed ID: 25759096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How type II CRISPR-Cas establish immunity through Cas1-Cas2-mediated spacer integration.
    Xiao Y; Ng S; Nam KH; Ke A
    Nature; 2017 Oct; 550(7674):137-141. PubMed ID: 28869593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in Cas9 Enhance the Rate of Acquisition of Viral Spacer Sequences during the CRISPR-Cas Immune Response.
    Heler R; Wright AV; Vucelja M; Bikard D; Doudna JA; Marraffini LA
    Mol Cell; 2017 Jan; 65(1):168-175. PubMed ID: 28017588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity.
    Charpentier E; Richter H; van der Oost J; White MF
    FEMS Microbiol Rev; 2015 May; 39(3):428-41. PubMed ID: 25994611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection and Validation of Spacer Sequences for CRISPR-Cas9 Genome Editing and Transcription Regulation in Bacteria.
    Grenier F; Lucier JF; Rodrigue S
    Methods Mol Biol; 2015; 1334():233-44. PubMed ID: 26404154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the CRISPR-Associated Genes by Rv2837c (CnpB) via an Orn-Like Activity in Tuberculosis Complex Mycobacteria.
    Zhang Y; Yang J; Bai G
    J Bacteriol; 2018 Apr; 200(8):. PubMed ID: 29378893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing.
    Li B; Zeng C; Dong Y
    Nat Protoc; 2018 May; 13(5):899-914. PubMed ID: 29622802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-cleavage activity of Cas6b in crRNA processing of two different CRISPR-Cas systems in Methanosarcina mazei Gö1.
    Nickel L; Ulbricht A; Alkhnbashi OS; Förstner KU; Cassidy L; Weidenbach K; Backofen R; Schmitz RA
    RNA Biol; 2019 Apr; 16(4):492-503. PubMed ID: 30153081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-CRISPR from a virulent streptococcal phage inhibits Streptococcus pyogenes Cas9.
    Hynes AP; Rousseau GM; Lemay ML; Horvath P; Romero DA; Fremaux C; Moineau S
    Nat Microbiol; 2017 Oct; 2(10):1374-1380. PubMed ID: 28785032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.